PHATPhathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III cli…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts The latest update on Phathom Pharmaceuticals centers on a reset in valuation anchors, with fair value moving from US$23.70 to US$21.50 as analysts revisit their price targets. This change reflects a more cautious tone in recent research, where Q2 results, revised 2026 revenue guidance, and fresh views on Voquezna's commercial path are all feeding into how targets are being set. As you read on, you will see what is driving the evolving narrative and how to keep track of the key signals. Stay... | ||
 PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range. | ||
 Phathom Pharmaceuticals Q2 Earnings Call Highlights Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan. The company report | ||
Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ... Phathom Pharmaceuticals Inc (PHAT) achieves milestone profitability and strong revenue growth, but faces physician friction in the prior authorization process for Voquezna. | ||
 Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2 Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||